Gene test may tailor chemo for stomach cancer patients
NCT ID NCT02366819
First seen May 05, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This study tested whether using a person's genetic information to adjust the dose of a chemotherapy drug (irinotecan) could help patients with advanced stomach or esophageal cancer. The goal was to see if this personalized approach could make surgery more successful by shrinking tumors. The trial involved 36 participants and was suspended, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kellogg Cancer Center - Evanston Hospital
Evanston, Illinois, 60201, United States
-
NorthShore University HealthSystem
Evanston, Illinois, 60201, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.